Additionally, osimertinib may be a reasonable option in the treatment of NSCLC, either after the first or second generation of EGFR‐TKI or in combination with pemetrexed or platinum doublet chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.